Request Demo
Last update 12 Apr 2025
RC-198
Last update 12 Apr 2025
Overview
Basic Info
Drug Type Fusion protein |
Synonyms RC 198, RC198 |
Target |
Action modulators |
Mechanism IL-15 modulators(Interleukin-15 modulators), IL-15Rα modulators(Interleukin-15 receptor subunit alpha modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure/Sequence
Sequence Code 20178944
Related
2
Clinical Trials associated with RC-198CTR20232546
一项在局部晚期不可切除或转移性实体瘤受试者中评估RC198安全性、耐受性、药代动力学特征、免疫原性和初步有效性的I期、首次人体、多中心、开放性研究
[Translation] A Phase I, first-in-human, multicenter, open-label study to evaluate the safety, tolerability, pharmacokinetic profile, immunogenicity, and preliminary efficacy of RC198 in subjects with locally advanced unresectable or metastatic solid tumors
NCT05867303
A Phase 1, First-in-Human, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Immunogenetic and Efficacy of RC198 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors
100 Clinical Results associated with RC-198
Login to view more data
100 Translational Medicine associated with RC-198
Login to view more data
100 Patents (Medical) associated with RC-198
Login to view more data
100 Deals associated with RC-198
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Colorectal Cancer | Phase 1 | China | 05 Jun 2023 | |
| Colorectal Cancer | Phase 1 | Australia | 05 Jun 2023 | |
| Locally Advanced Malignant Solid Neoplasm | Phase 1 | China | 05 Jun 2023 | |
| Locally Advanced Malignant Solid Neoplasm | Phase 1 | Australia | 05 Jun 2023 | |
| Melanoma | Phase 1 | China | 05 Jun 2023 | |
| Melanoma | Phase 1 | Australia | 05 Jun 2023 | |
| Non-Small Cell Lung Cancer | Phase 1 | China | 05 Jun 2023 | |
| Non-Small Cell Lung Cancer | Phase 1 | Australia | 05 Jun 2023 | |
| Renal Cell Carcinoma | Phase 1 | China | 05 Jun 2023 | |
| Renal Cell Carcinoma | Phase 1 | Australia | 05 Jun 2023 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free